Premium
In Case You Haven't Heard…
Publication year - 2021
Publication title -
alcoholism and drug abuse weekly
Language(s) - English
Resource type - Journals
eISSN - 1556-7591
pISSN - 1042-1394
DOI - 10.1002/adaw.33007
Subject(s) - waiver , buprenorphine , phone , schedule , license , certification , administration (probate law) , enforcement , political science , internet privacy , law , business , medicine , family medicine , opioid , management , computer science , linguistics , philosophy , receptor , economics
The MAT Act, the MATE Act and the TREATS Act are all in play now, designed to promote various forms of buprenorphine prescribing — some with specialized education, some without specialized education and some merely over the phone. Stay tuned for what is going to be a bumpy ride. The American Society of Addiction Medicine (ASAM) and the American Medical Association are all for freeing up their members from any kind of regulation. For its part, ASAM would like its trained and certified prescribers to have precedence. Everybody is pretty keen on the idea of getting fully reimbursed for doing something over the phone. Or maybe on video. The American Association for the Treatment of Opioid Dependence is concerned about patients. So is NAMA. What is clear, however, is that the x‐waiver itself, as it now stands, is doomed to extinction. The juggernaut against it is too great. Eight hours of training? No way, say doctors, we already have a Drug Enforcement Administration license and can prescribe Schedule II; buprenorphine is only Schedule III. We have covered the x‐waiver controversy in almost every issue this year. See our website for archived articles. More next week on TREATS.